Anetoderma

Back

Background

Anetoderma (anetos, Greek for slack) is a benign condition with focal loss of dermal elastic tissue, resulting in localized areas of flaccid or herniated saclike skin. The condition has been reported under various names, including macular atrophy, anetoderma maculosa, and atrophia maculosa cutis. Primary lesions consist of localized areas of flaccid skin, which can be macular, papular, or depressed. 

Historically, idiopathic lesions were classified based on a clinically inflammatory (Jadassohn-Pellizzari) or noninflammatory (Schweninger-Buzzi) onset. However, both types of lesions may be found in the same individual, and they are histologically similar. Currently, anetoderma is classified as either primary anetoderma, which is an idiopathic occurrence of atrophic lesions in areas of skin that appear normal prior to the onset of atrophy, or secondary anetoderma, which is preceded by an inflammatory, autoimmune, infectious, or neoplastic process. Both types may be associated with systemic diseases. A familial form that manifests as primary anetoderma has also been described.[1]

Pathophysiology

The exact cause of anetoderma is unknown. Possible explanations for the loss of elastic tissue include defective elastin synthesis, uncontrolled production of elastolytic enzymes, loss of elastolytic enzyme inhibitors, elastophagocytosis, or degeneration of elastic fibers secondary to local ischemia induced by microthromboses in dermal vessels.[2] Some investigators have proposed a possible common epitope between elastic fibers and phospholipids as an explanation for an autoimmune-mediated process.[2]

Elastolytic enzymes such as matrix metalloproteinases (MMPs) may be directly responsible for elastin degradation in anetoderma. Alternatively, they may act indirectly by modulating other inflammatory events, such as proteolytic activation of latent cytokines, which, in turn, may regulate the activity of other undiscovered elastolytic enzymes. Known elastolytic enzyme inhibitors include serine proteinase inhibitors (serpins) and tissue inhibitors of metalloproteinase (TIMPs).

An imbalance in levels of MMPs and TIMPs altering the rate of elastin turnover has been suggested as one explanation of the pathophysiology of anetoderma. Specifically, MMP-2 and MMP-9 have been suggested as possible culprits at the origin of elastic fiber destruction in anetoderma.[3]

Furthermore, a 2016 study involving nine patients with idiopathic anetoderma found that the dermal expression of fibulin-4 (which binds tropoelastin and is involved in various aspects of elastic fiber development) was significantly decreased in anetoderma when compared with healthy controls. These findings suggest that in addition to elastolytic overactivity, altered reassembly of elastic fibers may also play a significant role in the pathogenesis anetoderma.[4]

Epidemiology

Frequency

The exact incidence of anetoderma is unknown, but secondary anetoderma is probably more common than the primary form. Familial anetoderma is uncommon, with only 12 families reported in the literature.[5, 6, 7, 8] Inheritance may be autosomal dominant, autosomal recessive, or undefined.

Sex

Primary anetoderma occurs slightly more frequently in women than in men.

Age

Primary anetoderma usually presents between the second and fourth decades of life, although patients of all ages have been reported to develop anetoderma.[9, 10, 11]

Prognosis

Once developed, the lesions do not change over time.

History

Initial lesions may be noticed as crops of 1-2 cm, asymptomatic erythematous macules, plaques, or nodules that enlarge over weeks, possibly reaching several centimeters in diameter. Lesions appear on the upper arms, the trunk, the thighs, and less commonly on the neck, face, and rarely on distal extremities. Comorbid lesions may already exist. End-stage lesions do not change over time, and new lesions may continue to develop over years.

Physical Examination

Primary lesions of anetoderma present as discrete, flaccid areas of slack skin, which may be depressed, macular, or papular. Lesions may have overlying wrinkled skin. Lesions may be isolated or multiple. Lesions may slightly bulge like pouches and herniate into the skin upon palpation, a finding referred to as the "buttonhole" sign by some authors.[12]  See the images below.



View Image

Multiple lesions of anetoderma.



View Image

Close-up view of a single lesion of anetoderma.

On pressure, a normal ring of surrounding skin is felt. The scalp, the palms, the soles, and the mucous membranes are usually spared. A few to hundreds of lesions may form. These may coalesce and become indistinguishable from acquired cutis laxa.

Causes

Primary or idiopathic anetoderma originates from previously healthy skin with unknown pathogenesis. Various autoimmune, ocular, bony, cardiac, and other abnormalities have been reported with anetoderma, including the familial forms. Whether these findings are coincidental or related is unknown. Thus, a thorough history and a complete physical examination are essential.

The association with lupus erythematosus or other autoimmune disorders and primary anetoderma is well-established. This is owing to the frequent finding of antinuclear antibodies, antiphospholipid antibodies, hypocomplementemia, thyroid autoantibodies, and/or a positive lupus band test in patients who have anetoderma. However, criteria for diagnosis of systemic lupus erythematosus are typically not met.

Furthermore, studies have suggested a strong association between primary anetoderma and the presence of antiphospholipid antibodies, with or without a diagnosis of antiphospholipid antibody syndrome.[13] Primary anetoderma may appear years earlier than the classic signs of an autoimmune syndrome. It is therefore recommended to search for clinical and laboratory signs of an autoimmune disorder in every patient presenting with primary anetoderma.[14, 15, 16]

Familial anetoderma is a rare entity, which has only been reported in 12 families to date. Anetoderma was limited to the skin in some cases, while others were associated with extracutaneous abnormalities, particularly bone and/or cranial nerve anomalies.[1]

Anetoderma of prematurity is yet another entity occurring in very-low-birth-weight infants in neonatal intensive care units. Lesions usually present on the trunk and have been linked to the use of monitoring leads, leading to local hypoxia secondary to pressure on immature skin, thereby representing an acquired disorder.[17]

Additional associations that have been reported with primary anetoderma include the following:

Secondary anetoderma has been associated with myriad inflammatory, autoimmune, infectious, and neoplastic dermatological conditions. Associations that have been well-documented in the literature include the following:

Additional conditions that have been reported to be associated with secondary anetoderma in isolated case reports include the following:

Furthermore, external traumatic injuries that have been linked to the development of secondary anetoderma include the following:

Laboratory Studies

Laboratory testing for the presence of thyroid autoantibodies[55] and antiphospholipid antibodies in all patients who present with primary anetoderma is recommended. Antiphospholipid antibody tests include lupus anticoagulant, all isotypes of anticardiolipin, and anti-β2-glycoprotein I antibodies. The following laboratory tests may be considered if clinically indicated:

Histologic Findings

A perivascular and periadnexal lymphohistiocytic infiltrate is seen in the papillary dermis, upper reticular dermis, or both. Marked loss of elastic fibers is observed, although fine microfibrils may remain. Collagen fibers appear normal. Desmosine, a cross-linking compound found only in elastin, is reduced in lesional skin. Early lesions may show a pronounced monocytic infiltrate of predominantly T helper lymphocytes, but occasionally, the predominant cell types are histiocytes, neutrophils, or eosinophils. Scattered macrophages showing elastophagocytosis may be present. Microthromboses may be seen in individuals with anetoderma and antiphospholipid antibodies.

Direct immunofluorescence is usually not helpful, but findings similar to those of lupus erythematosus may be found,[56] with granular deposits of immunoglobulin G (IgG), immunoglobulin M (IgM), and/or complement (C3) along the dermoepidermal junction and blood vessels. Sometimes, fibrillar immunoglobulin and complement deposits are present in the papillary dermis. This probably corresponds to deposition on elastic tissue, although indirect immunofluorescence studies have failed to demonstrate elastic fiber autoantibodies.

Approach Considerations

To date, no effective treatment is available for anetoderma. Therapeutic options that have been used but have not shown consistent results include intralesional steroids, as well as systemic penicillin G, aspirin, phenytoin, dapsone, vitamin E, and niacin. Anecdotal reports have described topical epsilon-aminocaproic acid (an antifibrinolytic)[57] and oral colchicine[58] as potential treatments to prevent the development of new lesions.

Furthermore, isolated case reports have shown improvement of anetoderma lesions when treated with the following lasers:

Surgical excision is an option if lesions are small and few in numbers.

Long-Term Monitoring

For primary anetoderma, patients need periodic reevaluation for associated conditions not initially manifested. This evaluation includes a complete physical examination and appropriate screening laboratory tests.

Author

Anne Elizabeth Laumann, MBChB, MRCP(UK), FAAD, Professor of Dermatology, Northwestern University, The Feinberg School of Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Julia Sanger Minocha, MD, Resident Physician, Department of Medicine, Northwestern University, The Feinberg School of Medicine

Disclosure: Nothing to disclose.

Victoria Godinez-Puig, MD, Resident Physician, Department of Dermatology, Northwestern University, The Feinberg School of Medicine

Disclosure: Nothing to disclose.

Specialty Editors

David F Butler, MD, Former Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

Disclosure: Nothing to disclose.

Edward F Chan, MD, Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania School of Medicine

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Disclosure: Nothing to disclose.

Acknowledgements

Peter Fritsch, MD Chair, Department of Dermatology and Venereology, University of Innsbruck, Austria

Peter Fritsch, MD is a member of the following medical societies: American Dermatological Association, International Society of Pediatric Dermatology, and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Stephen C Ho, MD is a member of the following medical societies: American Academy of Dermatology, American Contact Dermatitis Society, American Society for Dermatologic Surgery, American Society for Laser Medicine and Surgery, American Society of Cosmetic Dermatology and Aesthetic Surgery, and Colorado Medical Society

Disclosure: Nothing to disclose.

Jin Mo Park, PhD Assistant Professor, Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School

Disclosure: Nothing to disclose.

Jenny Sun, MD Research Fellow, Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School

Disclosure: Nothing to disclose.

References

  1. Patrizi A, Neri I, Virdi A, Misciali C, D'Acunto C. Familial anetoderma: a report of two families. Eur J Dermatol. 2011 Sep-Oct. 21(5):680-5. [View Abstract]
  2. Weinstein S, Piette W. Cutaneous manifestations of antiphospholipid antibody syndrome. Hematol Oncol Clin North Am. 2008 Feb. 22(1):67-77, vi. [View Abstract]
  3. Kim JE, Sohn KM, Woo YJ, Jeong KH, Kim M, Lee JD, et al. A Clinicoimmunohistopathologic Study of Anetoderma: Is Protruding Type More Advanced in Stage Than Indented Type?. J Immunol Res. 2016. 2016:4325463. [View Abstract]
  4. Gambichler T, Reininghaus L, Skrygan M, Schulze HJ, Schaller J, Colato C, et al. Fibulin Protein Expression in Mid-dermal Elastolysis and Anetoderma: A Study of 23 Cases. Acta Derm Venereol. 2016 Jun 15. 96 (5):708-10. [View Abstract]
  5. Patrizi A, Neri I, Virdi A, Misciali C, D'acunto C. Familial anetoderma: a report of two families. Eur J Dermatol. 2011 Jul 1. [View Abstract]
  6. Friedman SJ, Venencie PY, Bradley RR, Winkelmann RK. Familial anetoderma. J Am Acad Dermatol. 1987 Feb. 16(2 Pt 1):341-5. [View Abstract]
  7. Thomas JE, Mehregan DR, Holland J, Mehregan DA. Familial anetoderma. Int J Dermatol. 2003 Jan. 42(1):75-7. [View Abstract]
  8. Zellman GL, Levy ML. Congenital anetoderma in twins. J Am Acad Dermatol. 1997 Mar. 36(3 Pt 1):483-5. [View Abstract]
  9. Goujon E, Beer F, Gay S, Sandre D, Gouyon JB, Vabres P. Anetoderma of prematurity: an iatrogenic consequence of neonatal intensive care. Arch Dermatol. 2010 May. 146(5):565-7. [View Abstract]
  10. Karrer S, Szeimies RM, Stolz W, Landthaler M. Primary Anetoderma in children: report of two cases and literature review. Pediatr Dermatol. 1996 Sep-Oct. 13(5):382-5. [View Abstract]
  11. Taïeb A, Dufillot D, Pellegrin-Carloz B, Calabet A, Clementy J, Guillard JM, et al. Postgranulomatous anetoderma associated with Takayasu's arteritis in a child. Arch Dermatol. 1987 Jun. 123(6):796-800. [View Abstract]
  12. Maari C, Powell J. Atrophies of connective tissue. Jean L. Bolognia, Joseph L. Jorizzo, and Julie V. Schaffer. Dermatology. Third. Elsevier Health Sciences; 6/18/2012. 2: 1631-40.
  13. Hodak E, Shamai-Lubovitz O, David M, Hazaz B, Katzenelson-Weissman V, Lahav M, et al. Immunologic abnormalities associated with primary anetoderma. Arch Dermatol. 1992 Jun. 128(6):799-803. [View Abstract]
  14. Staiger H, Saposnik M, Spiner RE, Schroh RG, Corbella MC, Hassan ML. Primary anetoderma: a cutaneous marker of antiphospholipid antibodies. Skinmed. 2011 May-Jun. 9(3):168-71. [View Abstract]
  15. de Souza EM, Daldon PE, Cintra ML. Anetoderma associated with primary antiphospholipid syndrome. J Am Acad Dermatol. 2007 May. 56(5):881-2. [View Abstract]
  16. Hodak E, David M. Primary anetoderma and antiphospholipid antibodies--review of the literature. Clin Rev Allergy Immunol. 2007 Apr. 32(2):162-6. [View Abstract]
  17. Goujon E, Beer F, Gay S, Sandre D, Gouyon JB, Vabres P. Anetoderma of prematurity: an iatrogenic consequence of neonatal intensive care. Arch Dermatol. 2010 May. 146(5):565-7. [View Abstract]
  18. Herrero-Gonzalez JE, Herrero-Mateu C. Primary anetoderma associated with primary Sjogren's syndrome. Lupus. 2002. 11(2):124-6. [View Abstract]
  19. Brenner S, Nemet P, Legum C. Jadassohn-type anetoderma in association with keratoconus and cataract. Ophthalmologica. 1977. 174(4):181-4. [View Abstract]
  20. Larsen DA, Sommerlund M, Bek T. Anetoderma. A possible new risk factor for subretinal neovascularization. Acta Ophthalmol. 2011 Feb. 89(1):e95. [View Abstract]
  21. O'Gorman SM, Sheahan K, Collins P. Cocaine, a culprit in anetoderma?. Clin Exp Dermatol. Aug 2015. 40:695-6. [View Abstract]
  22. Brenner S, Gazit E, Lieberman M, Ilie B, Krakowski A. Jadassohn-type anetoderma in association with protrusion of the teeth. Dermatologica. 1980. 161(5):334-9. [View Abstract]
  23. Connor CJ, Shchelochkov OA, Ciliberto H. Anetoderma in a patient with terminal osseous dysplasia with pigmentary defects. Am J Med Genet A. Oct 2015. 2459-62. [View Abstract]
  24. Kasper RC, Wood GS, Nihal M, LeBoit PE. Anetoderma arising in cutaneous B-cell lymphoproliferative disease. Am J Dermatopathol. 2001 Apr. 23(2):124-32. [View Abstract]
  25. Jubert C, Cosnes A, Clerici T, Gaulard P, Andre P, Revuz J, et al. Sjogren's syndrome and cutaneous B cell lymphoma revealed by anetoderma. Arthritis Rheum. 1993 Jan. 36(1):133-4. [View Abstract]
  26. Zattra, E, B. Pigozzi, et al. Anetoderma in cutaneous marginal-zone B-cell lymphoma. Clin Exp Dermatol. 2009. 34(8):945-948.
  27. Ferrara G, Cusano F, Robson A, Stefanato CM. Primary cutaneous marginal zone B-cell lymphoma with anetoderma: spontaneous involution plus de novo clonal expansion. J Cutan Pathol. 2011 Apr. 38(4):342-5. [View Abstract]
  28. Pezzetta S, Russo I, Brumana M, Marino F, Alaibac M. Exacerbation of a Primary Follicular Centre Cutaneous B-cell Lymphoma during Pregnancy and Resolution to Anetoderma After Delivery. Acta Derm Ve. 2016 Aug 23. 96(6):828-9. [View Abstract]
  29. Lee SM, Kim YJ, Chang SE. Pinhole carbon dioxide laser treatment of secondary anetoderma associated with juvenile xanthogranuloma. Dermatol Surg. 2012 Oct. 38(10):1741-3. [View Abstract]
  30. Trevisan G, Padovan C, Scaini MT, Cinco M, Floris R, Bonin S. Anetoderma associated with lyme disease: a case report. Acta Derm Venereol. 2008. 88(5):536-8. [View Abstract]
  31. de Souza EM, Ayres Vallarelli AF, Cintra ML, Vetter-Kauczok CS, Brocker EB. Anetodermic pilomatricoma. J Cutan Pathol. 2008 Aug 18. [View Abstract]
  32. Clement M, du Vivier A. Anetoderma secondary to syphilis. J R Soc Med. 1983 Mar. 76(3):223-4. [View Abstract]
  33. Emer J, Roberts D, Sidhu H, Phelps R, Goodheart H. Generalized Anetoderma after Intravenous Penicillin Therapy for Secondary Syphilis in an HIV Patient. J Clin Aesthet Dermatol. 2013 Aug. 6(8):23-8. [View Abstract]
  34. Crone AM, James MP. Acquired linear anetoderma following angular cheilitis. Br J Dermatol. 1998 May. 138(5):923-4. [View Abstract]
  35. Cockayne SE, Gawkrodger DJ. Hamartomatous congenital melanocytic nevi showing secondary anetoderma-like changes. J Am Acad Dermatol. 1998 Nov. 39(5 Pt 2):843-5. [View Abstract]
  36. Sheehan DJ, Madkan V, Strickling WA, Peterson CM. Atrophic dermatofibrosarcoma protuberans: a case report and reappraisal of the literature. Cutis. 2004 Oct. 74(4):237-42. [View Abstract]
  37. Ozkan S, Fetil E, Izler F, Pabucçuoglu U, Yalcin N, Gunes AT. Anetoderma secondary to generalized granuloma annulare. J Am Acad Dermatol. 2000 Feb. 42(2 Pt 2):335-8. [View Abstract]
  38. Kang HS, Paek JO, Lee MW, Yu HJ, Kim JS. Anetoderma developing in generalized granuloma annulare in an infant. Ann Dermatol. 2014 Apr. 26(2):283-5. [View Abstract]
  39. Ruiz-Rodriguez R, Longaker M, Berger TG. Anetoderma and human immunodeficiency virus infection. Arch Dermatol. 1992 May. 128(5):661-2. [View Abstract]
  40. Kalogeromitros D, Gregoriou S, Makris M, Georgala S, Kempuraj D, Theoharides TC. Secondary anetoderma associated with mastocytosis. Int Arch Allergy Immunol. 2007. 142(1):86-8. [View Abstract]
  41. Shalders K, Ilchyshyn A, Walzman M. Secondary anetoderma following molluscum contagiosum infection. Acta Derm Venereol. 2003. 83(6):461-2. [View Abstract]
  42. Requena L, Gonzalez-Guerra E, Angulo J, DeVore AE, Sangueza OP. Anetodermic mycosis fungoides: a new clinicopathological variant of mycosis fungoides. Br J Dermatol. 2008 Jan. 158(1):157-62. [View Abstract]
  43. Chaby G, Viseux V, Chatelain D, Denoeux JP, Lok C. [Myxofibrosarcoma associated with anetoderma]. Ann Dermatol Venereol. 2006 Jan. 133(1):35-7. [View Abstract]
  44. Velez D, Reina Duran T, Perez-Gala S, Fernandez JF. Rosetoid schwannoma (neuroblastoma-like) in association with an anetoderma. J Cutan Pathol. 2006 Aug. 33(8):573-6. [View Abstract]
  45. Johnson WC. Wilson's disease and penicillamine-induced anetoderma. Arch Dermatol. 1977. 113:976.
  46. Hirschel-Scholz S, Salomon D, Merot Y, Saurat JH. Anetodermic prurigo nodularis (with Pautrier's neuroma) responsive to arotinoid acid. J Am Acad Dermatol. 1991 Aug. 25(2 Pt 2):437-42. [View Abstract]
  47. Velez MJ, Mesinkovska N, Bergfeld WF. Anetoderma arising in Reed syndrome: a case report and review of the literature. J Cutan Pathol. May 2015. [View Abstract]
  48. Lee WJ, Yang JH, Chang SE, Lee MW, Choi JH, Moon KC. Secondary anetoderma overlying schwannoma. Acta Derm Venereol. 2009. 89(2):219-20. [View Abstract]
  49. Cho S, Jung JY, Lee JH. Treatment of Anetoderma Occurring After Resolution of Stevens-Johnson Syndrome Using an Ablative 10,600-nm Carbon Dioxide Fractional Laser. Dermatol Surg. 2012 Jan 17. [View Abstract]
  50. Ivanova II1, Kotzev IA, Atanassova MV, Gancheva DT, Pavlov SI, Krasnaliev IJ, et al. Wilson's disease in association with anetoderma. Clin J Gastroenterol. 2015 Feb. 8(1):52-6. [View Abstract]
  51. Prizant TL, Lucky AW, Frieden IJ, Burton PS, Suarez SM. Spontaneous atrophic patches in extremely premature infants. Anetoderma of prematurity. Arch Dermatol. 1996 Jun. 132(6):671-4. [View Abstract]
  52. Maffeis L, Pugni L, Pietrasanta C, Ronchi A, Fumagalli M, Gelmetti C, et al. Iatrogenic anetoderma of prematurity: a case report and review of the literature. Case Rep Dermatol Med. [View Abstract]
  53. Daoud MS, Dicken CH. Anetoderma after hepatitis B immunization in two siblings. J Am Acad Dermatol. 1997 May. 36(5 Pt 1):779-80. [View Abstract]
  54. Zaki I, Scerri L, Nelson H. Primary anetoderma: phagocytosis of elastic fibres by macrophages. Clin Exp Dermatol. 1994 Sep. 19(5):388-90. [View Abstract]
  55. Al Buainain H, Allam M. Anetoderma: Is It a Sign of Autoimmunity?. Case Rep Dermatol. 2009. 1(1):100-104. [View Abstract]
  56. Bergman R, Friedman-Birnbaum R, Hazaz B, Cohen E, Munichor M, Lichtig C. An immunofluorescence study of primary anetoderma. Clin Exp Dermatol. 1990 Mar. 15(2):124-30. [View Abstract]
  57. Reiss F, Linn E. The therapeutic effect of epsilon-aminocaproic acid on anetoderma Jadassohn. Dermatologica. 1973. 146(6):357-60. [View Abstract]
  58. Braun RP, Borradori L, Chavaz P, Masouye I, French L, Saurat JH. Treatment of primary anetoderma with colchicine. J Am Acad Dermatol. 1998 Jun. 38(6 Pt 1):1002-3. [View Abstract]
  59. Wang K, Ross NA, Saedi N. Anetoderma treated with combined 595-nm pulsed-dye laser and 1550-nm non-ablative fractionated laser. J Cosmet Laser Ther. 2016. 18:38-40. [View Abstract]

Multiple lesions of anetoderma.

Close-up view of a single lesion of anetoderma.

Multiple lesions of anetoderma.

Close-up view of a single lesion of anetoderma.